A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04492033 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 30, 2020
Last Update Posted : December 28, 2023
|
Sponsor:
Handok Inc.
Collaborators:
Compass Therapeutics
ABL Bio, Inc.
Information provided by (Responsible Party):
Handok Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | November 22, 2023 |
| Estimated Study Completion Date : | July 31, 2025 |